New target agents in the treatment of colorectal cancer patients

• HARRIS M: Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. (2004) 5:292-302.
   PubMed Web of Science ®Google Scholar
• HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57-70.
   PubMed Web of Science ®Google Scholar
• NYGREN P, LARSSON R: Overview of the clinical efficacy of investigational anticancer drugs. J. Int. Med. (2003) 253:46-75.
   PubMed Web of Science ®Google Scholar
• ROSS JS, SCHENKEIN DP, PIETRUSKO R et al.: Targeted therapies for cancer 2004. Am. J. Clin. Pathol. (2004) 122:598-609.
   PubMed Web of Science ®Google Scholar
• NYGREN P, SORBYE H, OSTERLUND P, PFEIFFER P: Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report. Acta Oncol. (2005) 44 (3):203-217.
   PubMed Web of Science ®Google Scholar
• MCMAHON G: VEGF receptor signaling in tumor angiogenesis. Oncologist (2000) 5(1):3-10.
   PubMedGoogle Scholar
• KLAGSBRUN M, D'AMORE PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. (1996) 7:259-270.
   PubMedGoogle Scholar
• ROBERTS WG, PALADE GE: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. (1995) 108:2369-2379.
   PubMed Web of Science ®Google Scholar
• LEE JC, CHOW NH, WANG ST et al.: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer (2000) 36:748-753.
   PubMed Web of Science ®Google Scholar
• CHOI HJ, HYUN MS, JUNG GJ et al.: Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology (1998) 55:575-581.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI Y, KITADAI Y, BUCANA CD et al.: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. (1995) 55:3964-3968.
   PubMed Web of Science ®Google Scholar
• WARREN RS, YUAN H, MATLI MR et al.: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. (1995) 95:1789-1797.
   PubMed Web of Science ®Google Scholar
• CARPENTER G, CHEN S: Epidermal growth factor. J. Biol. Chem. (1990) 265:7709-7712.
   PubMed Web of Science ®Google Scholar
• SALOMON DS, BRANDT R, CIARDIELLO F et al.: Epidermal growth factor related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. (1995) 19:183-232.
   PubMed Web of Science ®Google Scholar
• MAYER A, TAKIMOTO M, FRITZ E et al.: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer. Cancer (1993) 71:2454-2460.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Eng. J. Med. (2004) 350:2335-2342.
   PubMed Web of Science ®Google Scholar
• ROSEN L, MULAY M, LONG J et al.: Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:191.(Abstract).
   Google Scholar
• MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327-337.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, MICHAELSON MD, REDMAN BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24:16-24.
   PubMed Web of Science ®Google Scholar
• THOMAS A, MORGAN B, DREVS J et al.: Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging of two Phase I studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (2001):A279.
   Google Scholar
• STEWARD WP, THOMAS A, MORGAN B et al.: Expanded Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (2004) 22(14S):A3556.
   Google Scholar
• SCHLEUCHER N, TRARBACH T, JUNKER U et al.: Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (2004) 22(14S):A3558.
   PubMed Web of Science ®Google Scholar
• MAJOR P, TRARBACH T, LENZ H et al.: A meta-analysis of two randomized, double-blind, placebo-controlled, Phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):P352.
   Google Scholar
• WENG DE, USMAN N: Angiozyme: a novel angiogenesis inhibitor. Curr. Oncol. Rep. (2001) 3:141-146.
   PubMedGoogle Scholar
• VENOOK A, HURWITZ H, CUNNINGHAM C et al.: Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: results of a Phase II trial of a ribozyme targeting the premRNA for VEGFR-1 (angiozyme), in combination with chemotherapy. Annual Meeting of the American Society of Clinical Oncology (2003) 22:A1025.
   Web of Science ®Google Scholar
• HOLASH J, DAVIS S, PAPADOPOULOS N et al.: VEGF-trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA (2002) 99:11393-11398.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Eng. J. Med. (2004) 351:337-345.
   PubMed Web of Science ®Google Scholar
• TEWES M, SCHLEUCHER N, DIRSCH O et al.: Results of a Phase I trial of the humanized anti epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR expressing solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:A95.
   Google Scholar
• TABERNERO J, ROJO F, JIMENEZ E et al.: A Phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:192.
   Google Scholar
• VANHOEFER U, TEWES M, ROJO F et al.: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the EGF receptor. J. Clin. Oncol. (2004) 22:175-184.
   PubMed Web of Science ®Google Scholar
• VERONESE ML, O’DWYER PJ: Monoclonal antibodies in the treatment of colorectal cancer. Eur. J. Cancer (2004) 40:1292-1301.
   PubMed Web of Science ®Google Scholar
• CHUA YJ, CUNNINGHAM D: Panitumumab. Drugs Today (Barc.) (2006) 42(11):711-719.
   PubMed Web of Science ®Google Scholar
• HOY SM, WAGSTAFF AJ: Panitumumab: in the treatment of metastatic colorectal cancer. Drugs (2006) 66(15):2005-2014, 2015-2016.
   PubMed Web of Science ®Google Scholar
• FOON KA, YANG XD, WEINER LM et al.: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58:984-990.
   PubMed Web of Science ®Google Scholar
• FIGLIN RA, BELLDEGRUN AS, CRAWFORD J et al.: ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: Phase I clinical results. Proc. Am. Soc. Clin. Oncol. (2002) 21:A35.
   Web of Science ®Google Scholar
• ROSKOS L, LOHNER M, OSBORN K et al.: Low pharmacokinetic variability facilitates optimal dosing of ABX-EGF in cancer patients. Proc. Am. Soc. Clin. Oncol. (2002) 21:A362.
   Google Scholar
• MEROPOL NJ, BERLIN J, HECHT JR et al.: Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Annual Meeting of the American Society of Clinical Oncology (2003) 22:A1026.
   Google Scholar
• COHENURAM M, SAIF MW: Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 18(1):7-15.
   PubMed Web of Science ®Google Scholar
• HECHT J, MITCHELL E, BARANDA J et al.: Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1 – 9%) or negative (< 1%) levels of epidermal growth factor receptor (EGFr). Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A3547.
   Google Scholar
• BERLIN J, NEUBAUER M, SWANSON P et al.: Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing > 10% epidermal growth factor receptor (EGFr). Procedings of the 42nd ASCO Meeting. Atlanta, Georgia, USA (2006):A3548.
   Google Scholar
• BERLIN J, VAN CUTSEM E, PEETERS M et al.: Safety and efficacy of panitumumab monotherapy in the treatment of metastatic colorectal cancer (mCRC) – Summary of results across clinical studies. Procedings of the 31st ESMO Congress. Istanbul, Turkey (2006):O326.
   Google Scholar
• MALIK JR, HECHT A, PATNAIK A et al.: Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Proc. ASCO (2005):A3520.
   Google Scholar
• EL-RAYES BF, LORUSSO PM: Targeting the epidermal growth factor receptor. Br. J. Cancer (2004) 91:418-424.
   PubMed Web of Science ®Google Scholar
• FISCHER GA, KUO T, CHO CD et al.: A Phase II study of gefitinib in combination with FOLFOX-4 in patients with metastatic colorectal cancer. Annual Meeting of the American Society of Clinical Oncology (2004) 23:A3514.
   Google Scholar
• HAMMOND LA, FIGUEROA J, SCHWARTZBERG L et al.: Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa™), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:A137.
   Web of Science ®Google Scholar
• RANSON M, HAMMOND LA, FERRY D et al.: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J. Clin. Oncol. (2002) 20:2240-2250.
   PubMed Web of Science ®Google Scholar
• SEYMOUR L, GOSS G, STEWART D et al.: A translational research study of ZD1839 at a dose of 750 mg in patients with pretreated advanced or metastatic colorectal cancer: NCIC CTG IND.122. Ann. Oncol. (2002) 13(Suppl. 5):73.
   Google Scholar
• CHO CD, FISHER GA, HALSEY JZ, ADVANI RH, YUEN AR, SIKIC BI: A Phase I study of ZD1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies. Proc. Am. Soc. Clin. Oncol. (2002) 21:A38.
   Google Scholar
• DE BONO JS, HAMMOND LA, FIGUEROA J et al.: Phase I trial of ZD1839 (“Iressa”) in combination with 5-fluorouracil (5- FU) and leucovorin (LV) in patients with metastatic colorectal cancer. Presented at the British Cancer Research Meeting. June 30 – July 3. Glasgow, UK (2002).
   Google Scholar
• OZA AM, TOWNSLEY CA, SIU LL et al.: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Annual Meeting of the American Society of Clinical Oncology (2003) 22:A785.
   Web of Science ®Google Scholar
• TOWNSLEY C, MAJOR P, SIU LL, DANCEY J, VINCENT M, POND G. Phase II study of OSI-774 in patients with metastatic colorectal cancer. Eur. J. Cancer (2002) 38(Suppl. 7):S57.
   PubMed Web of Science ®Google Scholar
• HERBST RS: Erlotinib (Tarceva): an update on the clinical trial program. Semin. Oncol. (2003) 30(3 Suppl. 7):34-46.
   PubMed Web of Science ®Google Scholar
• GRUNWALD V, HIDALGO M: Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv. Exp. Med. Biol. (2003) 532:235-246.
   PubMed Web of Science ®Google Scholar
• ALBANELL J, ROJO F, AVERBUCH S et al.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. (2002) 20:110-124.
   PubMed Web of Science ®Google Scholar
• DANESHMAND M, PAROLIN DA, HIRTE HW et al.: A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin. Cancer Res. (2003) 9:2457-2464.
   PubMed Web of Science ®Google Scholar
• MALIK SN, SIU LL, ROWINSKY EK et al.: Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin. Cancer Res. (2003) 9:2478-2486.
   PubMed Web of Science ®Google Scholar
• CASADO E, FOLPRECHT G, PAZ ARES L et al.: A Phase I/IIA pharmacokinetic and serial skin and tumour pharmacodynamic study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) regimen in patients with advanced colorectal cancer. Annual Meeting of the American Society of Clinical Oncology (2004) 23:A3543.
   Google Scholar
• ARNOLD D, PEINERT S, VOIGT W, SCHMOLL HJ: Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist (2006) 11(6):602-611.
   PubMed Web of Science ®Google Scholar
• SHARMA S, KEMENY N, KELSEN DP et al.: A Phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann. Oncol. (2002) 13:1067-1071.
   PubMed Web of Science ®Google Scholar
• RAO S, CUNNINGHAM D, DE GRAMONT A et al.: Phase III double-blind placebocontrolled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. (2004) 22:3950-3957.
   PubMed Web of Science ®Google Scholar
• CRIPPS MC, FIGUEREDO AT, OZA AM et al.: Phase II randomised study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group study. Clin. Cancer Res. (2002) 8:2188-2192.
   PubMed Web of Science ®Google Scholar
• SENDEROWICZ AM, HEADLEE D, STINSON SF et al.: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. (1998) 16:2986-2999.
   PubMed Web of Science ®Google Scholar
• AKLILU M, KINDLER HL, DONEHOWER RC, MANI S, VOKES EE: Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann. Oncol. (2003) 14:1270-1273.
   PubMed Web of Science ®Google Scholar
• MOTWANI M, JUNG C, SIROTNAK FM et al.: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin. Cancer Res. (2001) 7:4209-4219.
   PubMed Web of Science ®Google Scholar
• SHAH MA, KORTMANSKY J, GONEN M et al.: A Phase I/pharmacologic study of weekly sequential irinotecan (CPT) and flavopiridol (F). Proc. Am. Soc. Clin. Oncol. (2002) 21:A373.
   Google Scholar
• GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer. Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Gastrointestinal Cancers Symposium (2005) A:169a.
   Google Scholar
• TEJPAR S, PEETERS M, HUMBLET Y et al.: Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): preliminary data. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (2006):A3554.
   Google Scholar
• ALEKSHUN T, GARRETT C: Targeted therapies in the treatment of colorectal cancers. Cancer Control (2005) 12(2):105-110.
   PubMedGoogle Scholar
• KOBAYASHI H, HANDE KR, BERLIN JD et al.: Phase I results of ABT-751, a novel microtubulin inhibitor, administered daily, 7 every 3 weeks. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (2004) 22(14S):A2079.
   Google Scholar
• CHO SY, ADAMSON PC, HAGEY AE et al.: Phase I trial and pharmacokinetic study of ABT-751, an orally bioavailable tubulin binding agent, in pediatric patients with refractory solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (2004) 22(14S):A2080.
   Google Scholar
• GARRETT C, DINWOODIE W, ROBERT F et al.: Phase I clinical studies of AG2037, a potent and novel inhibitor of glycinamide ribonucleotide formyltransferase. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (2002):A429.
   Google Scholar
• SYED SK, BEERAM M, TAKIMOTO CH et al.: Phase I and pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (2004) 22(14S):A2028.
   Google Scholar
• BEERAM M, TAKIMOTO CH, GADGEEL SM et al.: A Phase I and pharmacokinetic (PK) study of DJ-927, an orally administered taxane, in patients with advanced malignancies. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (2003):A524.
   Google Scholar
• HOLEN KD, SYED S, HANNAH AL et al.: Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. (2004) 22(14S):A2024.
   Web of Science ®Google Scholar
• PENG B, HAYES M, RESTA D et al.: Pharmacokinetics and pharmacodynamics of imatinib in a Phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. (2004) 22:935-942.
   PubMed Web of Science ®Google Scholar
• HECHT JR, MITCHELL EP, BARANDA J et al.: Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysis. J. Clin. Oncol., 2006 ASCO Annual Meeting Proceedings Part I. (2006) 24(18S):A350.
   Google Scholar
• PEETERS M, VAN CUTSEM E, SALVATORE S et al.: A Phase III, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) versus BSC in patients (pts) with metastatic colorectal cancer (mCRC). Proceedings, Annual Meeting of the American Association for Cancer Research. Washington DC, USA (1 – 5 April 2006).
   Google Scholar

Websites

• http://www.cancer.org/downloads/STT/EstimatedNewCancerCases ByState2007OldMethod.pdf American Cancer Society (2007).
   Google Scholar
• http://www.asco.org DEMETRI G, VAN OOSTEROM AT, GARRETT C et al.: Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate (IM) therapy in a Phase III trial. Paper presented at: 2006 Gastrointestinal Cancers Symposium: Multidisciplinary Approaches to the Prevention, Diagnosis, and Therapy of GI Cancers. 26 – 28 January 2006, San Francisco, CA (Abstract 8).
   Google Scholar
• http://www.asco.org LENZ H, MARSHALL J, ROSEN L et al.: Phase II trial of SU11248 in patients with metastatic colorectal cancer (MCRC) after failure of standard chemotherapy. Paper presented at: 2006 Gastrointestinal Cancers Symposium: Multidisciplinary Approaches to the Prevention, Diagnosis, and Therapy of GI Cancers. 26 – 28 January 2006, San Francisco, CA (Abstract 241).
   Google Scholar